T1	intervention 39 71	recombinant human interleukin-11
T2	condition 83 120	chemotherapy-induced thrombocytopenia
T3	eligibility 124 209	patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin
T4	control 850 857	placebo
T5	duration 903 916	10 or 17 days
T6	No-of-participants 958 971	Seventy-seven
T7	No-of-participants 1050 1061	Sixty-seven
T8	outcome 1337 1358	platelet transfusions
T9	intervention-value 1360 1362	27
T10	intervention-participants 1366 1368	40
T11	intervention-value 1370 1373	68%
T12	control-value 1449 1451	15
T13	control-participants 1455 1457	37
T14	control-value 1459 1462	41%
T15	outcome 1726 1740	adverse events
